Cargando…
Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis
BACKGROUND: Mucosal healing (MH) evaluated by endoscopy is a novel target of therapy in UC as it is associated with improved long-term outcomes. It is defined based on the Mayo endoscopic score (MES), but it is still to define whether a value of MES 0 or 1 should be the target. The purpose of this p...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895505/ https://www.ncbi.nlm.nih.gov/pubmed/35240984 http://dx.doi.org/10.1186/s12876-022-02157-5 |
_version_ | 1784662939992588288 |
---|---|
author | Viscido, Angelo Valvano, Marco Stefanelli, Gianpiero Capannolo, Annalisa Castellini, Chiara Onori, Eugenia Ciccone, Antonio Vernia, Filippo Latella, Giovanni |
author_facet | Viscido, Angelo Valvano, Marco Stefanelli, Gianpiero Capannolo, Annalisa Castellini, Chiara Onori, Eugenia Ciccone, Antonio Vernia, Filippo Latella, Giovanni |
author_sort | Viscido, Angelo |
collection | PubMed |
description | BACKGROUND: Mucosal healing (MH) evaluated by endoscopy is a novel target of therapy in UC as it is associated with improved long-term outcomes. It is defined based on the Mayo endoscopic score (MES), but it is still to define whether a value of MES 0 or 1 should be the target. The purpose of this paper is to present the results of a systematic review with meta-analysis which compares long-term outcomes of patients in steroid-free clinical remission with MES 0 with those with MES 1. METHODS: A systematic electronic search of the literature was performed using Medline, Scopus, and CENTRAL through December 2020 (PROSPERO n:CRD42020179333). The studies concerned UC patients, in steroid-free clinical remission, with MES of 0 or 1, and with at least 12-months of follow-up. RESULTS: Out of 4611 citations, 15 eligible studies were identified. Increases in clinical relapse among patients with MES 1 were observed in all the studies included in this review, suggesting that MES of 1 have a higher risk of relapse than a score of 0. MES 0 patients displayed a lower risk of clinical relapse (OR 0.33; 95% CI 0.26–0.43; I(2) 13%) irrespective of the follow-up time (12-months or longer). On the other hand, no differences were found comparing MES 0 versus MES 1 about the risk of hospitalization or colectomy. CONCLUSIONS: MES 0 is associated with a lower rate of clinical relapse than is MES 1. For this reason, MES 0, rather than MES 0–1, should be considered the therapeutic target for patients with UC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-022-02157-5. |
format | Online Article Text |
id | pubmed-8895505 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88955052022-03-10 Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis Viscido, Angelo Valvano, Marco Stefanelli, Gianpiero Capannolo, Annalisa Castellini, Chiara Onori, Eugenia Ciccone, Antonio Vernia, Filippo Latella, Giovanni BMC Gastroenterol Research Article BACKGROUND: Mucosal healing (MH) evaluated by endoscopy is a novel target of therapy in UC as it is associated with improved long-term outcomes. It is defined based on the Mayo endoscopic score (MES), but it is still to define whether a value of MES 0 or 1 should be the target. The purpose of this paper is to present the results of a systematic review with meta-analysis which compares long-term outcomes of patients in steroid-free clinical remission with MES 0 with those with MES 1. METHODS: A systematic electronic search of the literature was performed using Medline, Scopus, and CENTRAL through December 2020 (PROSPERO n:CRD42020179333). The studies concerned UC patients, in steroid-free clinical remission, with MES of 0 or 1, and with at least 12-months of follow-up. RESULTS: Out of 4611 citations, 15 eligible studies were identified. Increases in clinical relapse among patients with MES 1 were observed in all the studies included in this review, suggesting that MES of 1 have a higher risk of relapse than a score of 0. MES 0 patients displayed a lower risk of clinical relapse (OR 0.33; 95% CI 0.26–0.43; I(2) 13%) irrespective of the follow-up time (12-months or longer). On the other hand, no differences were found comparing MES 0 versus MES 1 about the risk of hospitalization or colectomy. CONCLUSIONS: MES 0 is associated with a lower rate of clinical relapse than is MES 1. For this reason, MES 0, rather than MES 0–1, should be considered the therapeutic target for patients with UC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12876-022-02157-5. BioMed Central 2022-03-03 /pmc/articles/PMC8895505/ /pubmed/35240984 http://dx.doi.org/10.1186/s12876-022-02157-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Viscido, Angelo Valvano, Marco Stefanelli, Gianpiero Capannolo, Annalisa Castellini, Chiara Onori, Eugenia Ciccone, Antonio Vernia, Filippo Latella, Giovanni Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis |
title | Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis |
title_full | Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis |
title_fullStr | Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis |
title_full_unstemmed | Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis |
title_short | Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis |
title_sort | systematic review and meta-analysis: the advantage of endoscopic mayo score 0 over 1 in patients with ulcerative colitis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8895505/ https://www.ncbi.nlm.nih.gov/pubmed/35240984 http://dx.doi.org/10.1186/s12876-022-02157-5 |
work_keys_str_mv | AT viscidoangelo systematicreviewandmetaanalysistheadvantageofendoscopicmayoscore0over1inpatientswithulcerativecolitis AT valvanomarco systematicreviewandmetaanalysistheadvantageofendoscopicmayoscore0over1inpatientswithulcerativecolitis AT stefanelligianpiero systematicreviewandmetaanalysistheadvantageofendoscopicmayoscore0over1inpatientswithulcerativecolitis AT capannoloannalisa systematicreviewandmetaanalysistheadvantageofendoscopicmayoscore0over1inpatientswithulcerativecolitis AT castellinichiara systematicreviewandmetaanalysistheadvantageofendoscopicmayoscore0over1inpatientswithulcerativecolitis AT onorieugenia systematicreviewandmetaanalysistheadvantageofendoscopicmayoscore0over1inpatientswithulcerativecolitis AT cicconeantonio systematicreviewandmetaanalysistheadvantageofendoscopicmayoscore0over1inpatientswithulcerativecolitis AT verniafilippo systematicreviewandmetaanalysistheadvantageofendoscopicmayoscore0over1inpatientswithulcerativecolitis AT latellagiovanni systematicreviewandmetaanalysistheadvantageofendoscopicmayoscore0over1inpatientswithulcerativecolitis |